Literature DB >> 26832730

Biomarkers for the identification of precursor polyps of colorectal serrated adenocarcinomas.

José García-Solano1,2, María Eulalia García-Solano1, Daniel Torres-Moreno1, Pablo Carbonell3, Javier Trujillo-Santos4, Miguel Pérez-Guillermo1, Pablo Conesa-Zamora5,6.   

Abstract

BACKGROUND: In contrast to conventional colorectal carcinomas (CCs), which develop through a so-called chromosome instability or suppressor phenotype pathway, the sequence of events leading from precursor polyps/adenomas to serrated adenocarcinomas (SACs), which are more aggressive and exhibit a poorer survival than CCs, is as yet not clearly defined. Here, we aimed at detecting protein and DNA biomarkers for SAC in a series of primary colorectal polyps.
METHODS: In total 303 colorectal polyps were included: 121 serrated polyps (33 hyperplastic polyps, 37 sessile serrated adenomas (SSA), 51 traditional serrated adenomas (TSA)), 143 conventional polyps (72 tubular polyps, 34 tubulovillous polyps, 37 villious adenomas), and 39 bi-phenotypic serrated-conventional polyps. The protein biomarkers tested were deduced from previously published SAC and CC expression profiling studies. A representative subset of 106 polyps was selected for DNA biomarker analyses, i.e., proto-oncogene mutation and microsatellite instability (MSI) status. In order to confer proper weight to each biomarker, a multivariate logistic regression model was employed.
RESULTS: We found that serrated and conventional polyps differed in most of the SAC biomarkers tested. Of these biomarkers, FSCN1 showed the largest difference in expression (p = 0.0001). Despite sharing a serrated morphology, we found that SSAs and TSAs differed considerably with respect to anatomical location, expression of EPHB2 and PTCH1, presence of the V600E BRAF mutation and MSI status. Logistic regression analysis revealed that SSA was the polyp type that shared most biomarkers with SAC.
CONCLUSION: Based on the shared presence of protein and molecular biomarkers, especially FSCN1 expression, SSA may serve as a precursor lesion of SAC. Biomarker assessment may help in discerning colorectal carcinogenic routes with distinct prognostic implications.

Entities:  

Keywords:  Biomarkers; Carcinogenesis; Colorectal cancer; Serrated adenocarcinoma; Serrated polyp

Mesh:

Substances:

Year:  2016        PMID: 26832730     DOI: 10.1007/s13402-016-0269-5

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  27 in total

1.  The risk of metachronous neoplasia in patients with serrated adenoma.

Authors:  Rajeka Lazarus; Oili E Junttila; Tuomo J Karttunen; Markus J Mäkinen
Journal:  Am J Clin Pathol       Date:  2005-03       Impact factor: 2.493

Review 2.  UK guidance for the pathological reporting of serrated lesions of the colorectum.

Authors:  Adrian C Bateman; Neil A Shepherd
Journal:  J Clin Pathol       Date:  2015-04-30       Impact factor: 3.411

3.  Histological overlap between colorectal villous/tubulovillous and traditional serrated adenomas.

Authors:  Sara Hafezi-Bakhtiari; Lai Mun Wang; Richard Colling; Stefano Serra; Runjan Chetty
Journal:  Histopathology       Date:  2014-11-13       Impact factor: 5.087

4.  Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subset of colorectal carcinoma.

Authors:  José García-Solano; Miguel Pérez-Guillermo; Pablo Conesa-Zamora; Jesús Acosta-Ortega; Javier Trujillo-Santos; Pablo Cerezuela-Fuentes; Markus J Mäkinen
Journal:  Hum Pathol       Date:  2010-07-01       Impact factor: 3.466

5.  Immunohistochemical expression profile of β-catenin, E-cadherin, P-cadherin, laminin-5γ2 chain, and SMAD4 in colorectal serrated adenocarcinoma.

Authors:  José García-Solano; Pablo Conesa-Zamora; Javier Trujillo-Santos; Daniel Torres-Moreno; Markus J Mäkinen; Miguel Pérez-Guillermo
Journal:  Hum Pathol       Date:  2011-12-29       Impact factor: 3.466

6.  Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours.

Authors:  Dong Li Guo; Ji Zhang; Siu Tsan Yuen; Wai Yin Tsui; Annie S Y Chan; Coral Ho; Jiafu Ji; Suet Yi Leung; Xin Chen
Journal:  Carcinogenesis       Date:  2005-11-04       Impact factor: 4.944

7.  Serrated lesions of the colorectum: review and recommendations from an expert panel.

Authors:  Douglas K Rex; Dennis J Ahnen; John A Baron; Kenneth P Batts; Carol A Burke; Randall W Burt; John R Goldblum; José G Guillem; Charles J Kahi; Matthew F Kalady; Michael J O'Brien; Robert D Odze; Shuji Ogino; Susan Parry; Dale C Snover; Emina Emilia Torlakovic; Paul E Wise; Joanne Young; James Church
Journal:  Am J Gastroenterol       Date:  2012-06-19       Impact factor: 10.864

Review 8.  Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society.

Authors:  Sidney J Winawer; Ann G Zauber; Robert H Fletcher; Jonathon S Stillman; Michael J O'Brien; Bernard Levin; Robert A Smith; David A Lieberman; Randall W Burt; Theodore R Levin; John H Bond; Durado Brooks; Tim Byers; Neil Hyman; Lynne Kirk; Alan Thorson; Clifford Simmang; David Johnson; Douglas K Rex
Journal:  Gastroenterology       Date:  2006-05       Impact factor: 22.682

9.  Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer.

Authors:  J R Jass; K Baker; I Zlobec; T Higuchi; M Barker; D Buchanan; J Young
Journal:  Histopathology       Date:  2006-08       Impact factor: 5.087

10.  The actin-bundling protein fascin is overexpressed in colorectal adenomas and promotes motility in adenoma cells in vitro.

Authors:  D Qualtrough; K Singh; N Banu; C Paraskeva; M Pignatelli
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

View more
  5 in total

1.  Novel anti-invasive properties of a Fascin1 inhibitor on colorectal cancer cells.

Authors:  Silvia Montoro-García; Begoña Alburquerque-González; Ángel Bernabé-García; Manuel Bernabé-García; Priscila Campioni Rodrigues; Helena den-Haan; Irene Luque; Francisco José Nicolás; Horacio Pérez-Sánchez; María Luisa Cayuela; Tuula Salo; Pablo Conesa-Zamora
Journal:  J Mol Med (Berl)       Date:  2020-01-29       Impact factor: 4.599

2.  Epigenome-Wide DNA Methylation Profiling of Normal Mucosa Reveals HLA-F Hypermethylation as a Biomarker Candidate for Serrated Polyposis Syndrome.

Authors:  Gerhard Jung; Eva Hernández-Illán; Juan J Lozano; Julia Sidorova; Jenifer Muñoz; Yasuyuki Okada; Enrique Quintero; Goretti Hernandez; Rodrigo Jover; Sabela Carballal; Miriam Cuatrecasas; Lorena Moreno; Mireia Diaz; Teresa Ocaña; Ariadna Sánchez; Liseth Rivero; Oswaldo Ortiz; Joan Llach; Antoni Castells; Maria Pellisé; Ajay Goel; Eduard Batlle; Francesc Balaguer
Journal:  J Mol Diagn       Date:  2022-04-18       Impact factor: 5.341

3.  Hyper-Methylated Loci Persisting from Sessile Serrated Polyps to Serrated Cancers.

Authors:  Angeline S Andrew; John A Baron; Lynn F Butterly; Arief A Suriawinata; Gregory J Tsongalis; Christina M Robinson; Christopher I Amos
Journal:  Int J Mol Sci       Date:  2017-03-02       Impact factor: 5.923

4.  Tracking the Antibody Immunome in Sporadic Colorectal Cancer by Using Antigen Self-Assembled Protein Arrays.

Authors:  María González-González; José María Sayagués; Luis Muñoz-Bellvís; Carlos Eduardo Pedreira; Marcello L R de Campos; Jacinto García; José Antonio Alcázar; Patrick F Braz; Breno L Galves; Luis Miguel González; Oscar Bengoechea; María Del Mar Abad; Juan Jesús Cruz; Lorena Bellido; Emilio Fonseca; Paula Díez; Pablo Juanes-Velasco; Alicia Landeira-Viñuela; Quentin Lecrevisse; Enrique Montalvillo; Rafael Góngora; Oscar Blanco; José Manuel Sánchez-Santos; Joshua LaBaer; Alberto Orfao; Manuel Fuentes
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

5.  Two novel colorectal cancer risk loci in the region on chromosome 9q22.32.

Authors:  Jessada Thutkawkorapin; Hovsep Mahdessian; Tom Barber; Simone Picelli; Susanna von Holst; Johanna Lundin; Laura Valle; Vinaykumar Kontham; Tao Liu; Daniel Nilsson; Xiang Jiao; Annika Lindblom
Journal:  Oncotarget       Date:  2018-01-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.